NCT02967094

Brief Summary

Study was designed to evaluate efficacy of mucolytic solution ingested before upper endoscopy on visibility of gastric mucosa.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
150

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Nov 2016

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2016

Completed
9 days until next milestone

First Submitted

Initial submission to the registry

November 10, 2016

Completed
7 days until next milestone

First Posted

Study publicly available on registry

November 17, 2016

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2017

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2017

Completed
Last Updated

November 29, 2016

Status Verified

November 1, 2016

Enrollment Period

4 months

First QC Date

November 10, 2016

Last Update Submit

November 27, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • "Visibility score" evaluated by blinded performing endoscopist

    "Visibility score" (0-25 points) counted as the sum of visibility score in the esophagus (0-5), fundus (0-5), corpus (0-5) and atrum (0-5) of the stomach and in the duodenum (0-5).

    through study completion, an average of 3 months

Secondary Outcomes (3)

  • "Visibility score" evaluated by three blinded endoscopists using 11 endoscopic images captured during endoscopy.

    through study completion, an average of 3 months

  • Residual fluid in the stomach evaluated by blinded performing endoscopist

    through study completion, an average of 3 months

  • Duration of endoscopy

    through study completion, an average of 3 months

Study Arms (3)

A - mucolytic solution

EXPERIMENTAL

Mucolytic solution consisting of 100 ml of water, 100 mg of simethicon and 400 mg of N-acetylcystein administered 30 minutes prior to upper endoscopy.

Drug: Administration of mucolytic solution before upper endoscopy (Espumisan, ACC long)

B - no intervention

NO INTERVENTION

Upper endoscopy without neither mucolytic solution nor water prior to upper endoscopy.

C - water

PLACEBO COMPARATOR

100 ml of water given 30 minutes prior to upper endoscopy.

Drug: Administration of water before upper endoscopy

Interventions

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • age \> 18 years
  • signed informed consent
  • diagnostic gastroscopy

You may not qualify if:

  • age \< 18 years
  • interventional gastroscopy
  • known disease of the upper GI tract and/or history of surgery of GI tract
  • gastroscopy indicated of bleeding, dysphagia or ileus
  • liver cirrhosis
  • general anesthesia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Digestive Diseases Center

Ostrava, 70384, Czechia

RECRUITING

Related Publications (1)

  • Stepan M, Falt P, Pipek B, Fojtik P, Hanousek M, Hill M, Urban O. Administration of mucolytic solution before upper endoscopy - double-blind, monocentric, randomized study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2023 Mar;167(1):69-73. doi: 10.5507/bp.2021.038. Epub 2021 Jun 22.

MeSH Terms

Conditions

Stomach Neoplasms

Interventions

Espumisan

Condition Hierarchy (Ancestors)

Gastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesStomach Diseases

Study Officials

  • Premysl Falt, M.D., Ph.D.

    Digestive Diseases Center, Vítkovice Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Premysl Falt, M.D., Ph.D.

CONTACT

Barbora Pipek, M.D.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principle Investigator

Study Record Dates

First Submitted

November 10, 2016

First Posted

November 17, 2016

Study Start

November 1, 2016

Primary Completion

March 1, 2017

Study Completion

May 1, 2017

Last Updated

November 29, 2016

Record last verified: 2016-11

Data Sharing

IPD Sharing
Will not share

Locations